Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players. This dynamic can trouble even the most skilled investors, but luckily for you, we started StockStory to help you navigate these trade-offs and uncover exceptional companies that break the mold. That said, here is one large-cap stock that still has big upside potential and two that could be stalling. Two Large-Cap Stocks to Sell: AT&T (T) Market Cap: $196.7 billion Founded by Alexander Graham Bell, AT&T (NYSE:T) is a multinational telecomm conglomerate providing a range of communications and internet services. Why Do We Think T Will Underperform? Annual sales declines of 7.3% for the past five years show its products and services struggled to connect with the market Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 10.9% annually, worse than its revenue ROIC of 3.3% reflects management’s challenges in identifying attractive investment opportunities AT&T is trading at $27.30 per share, or 13.1x forward P/E. Read our free research report to see why you should think twice about including T in your portfolio, it’s free. Vertex Pharmaceuticals (VRTX) Market Cap: $111.5 billion Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ:VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management. Why Are We Wary of VRTX? Earnings per share fell by 15.6% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 58.8 percentage points Waning returns on capital imply its previous profit engines are losing steam At $440 per share, Vertex Pharmaceuticals trades at 23.4x forward P/E. If you’re considering VRTX for your portfolio, see our FREE research report to learn more. One Large-Cap Stock to Buy: Lululemon (LULU) Market Cap: $38.32 billion Originally serving yogis and hockey players, Lululemon (NASDAQ:LULU) is a designer, distributor, and retailer of athletic apparel for men and women. Why Should You Buy LULU? Locations open for at least a year are seeing increased demand as same-store sales have averaged 8.2% growth over the past two years Collection of products is difficult to replicate at scale and results in a best-in-class gross margin of 58.8% Robust free cash flow margin of 16% gives it many options for capital deployment Story Continues Lululemon’s stock price of $318.96 implies a valuation ratio of 20.8x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free. High-Quality Stocks for All Market Conditions Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
1 Large-Cap Stock to Target This Week and 2 to Question
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...